The development of a neovascular supply (angiogenesis) is a major aspect of tumorigenesis. Recent work has indicated that vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis. In vitro and in vivo studies have demonstrated that an anti-VEGF antibody is capable of suppressing the growth of human tumor cell lines. The following study was conducted in tumor-bearing nude mice to evaluate the concentration-response relationship of murine anti-VEGF monoclonal antibody (muMAb VEGF) so that an efficacious plasma concentration of the recombinant humanized form (rhuMAb VEGF) in cancer patients could be estimated. (This study was included in our Investigational New Drug application to support the clinical dosing regimen and projected human safety factors for the toxicology program.) Additionally, the growth dynamics of the tumors were evaluated as a function of dose to explore whether a mechanismic interpretation of tumor growth inhibition by muMAb VEGF is possible. On day 1, A673 human rhabdomyosarcoma cells (2 X 106 cells/mouse) were injected subcutaneously in 188 beige nude mice (16-24 g). Treatment with muMAb VEGF (0.05-5.0 mg/kg; n = 24/group), phosphate-buffered saline (n = 10), or anti-gp120 isotype-matched control antibody (5.0 mg/kg; n =10) began 24 hr later. Each animal received intraperitoneal injections of test material twice weekly for 4 wk. Immediately prior to each dose, 2 mice from each muMAb VEGF group were selected randomly, and plasma was collected for pharmacokinetic evaluation; at the end of the study, samples were collected from all animals for pharmacokinetic evaluation. Tumor dimensions were recorded weekly, and at the end of the study, tumor weight and dimensions were recorded. Satisfactory tumor suppression in nude mice was achieved at muMAb VEGF doses of &ge;2.5 mg/kg, where the average trough muMAb VEGF plasma concentration was 30 &mu;g/ml (concentrations in individual animals >10 &mu;g/ml). Assuming the pharmacokinetics of rhuMAb VEGF in patients will resemble the pharmacokinetics of a similar humanized anticancer monoclonal antibodies, a clinical dosing regimen was designed to maintain the rhuMAb VEGF plasma concentration in this efficacious range. This study shows an approach that can be used to estimate a human dosing regimen from preclinical pharmacokinetic/pharmacodynamic data. Because we have just initiated clinical trials with rhuMAb VEGF, we cannot judge clinical outcome in relation to these preclinical predictions; nonetheless, it is hoped that by sharing our approach and thought processes with other investigators we can assist the discovery and development of anticancer therapeutics.
INTRODUCTION
The development of a vascular supply is a fundamental requirement for organ development and differentiation during embryogenesis and for wound healing and reproductive functions in the adult (10, 11) . Angiogenesis is also implicated in the pathogenesis of a variety of disorders : proliferative retinopathies, age-related macular degeneration, tumors, rheumatoid arthritis, and psoriasis (6, 7) . In proliferative retinopathies and age-related macular degeneration, the new blood vessels are directly responsible for many of the destructive events characteristic of these conditions. Leakage and bleeding followed by organization of the clot and fibrosis may ultimately lead to retinal detachment or irreversible damage to the macula (9) . Conversely, tumor-associated neovascularization, by establishing continuity with the systemic circulation, allows the tumor cells to express their critical growth advantage and facilitates metastasis (6, 7) . A correlation has been observed among density of microvessels in primary breast carcinoma sections, nodal metastases, and survival (12, 20, 23) . Similarly, a correlation has been reported between vascularity and invasive behavior in a variety of other tumors (2, 16, 18, 21) . These findings have led several investigators to conclude that the density of blood vessels in tumor sections is an independent predictor of outcome in cancer patients (2, 16, 18, 21) .
The search for potential regulators of angiogenesis has yielded numerous candidates, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-a, TGF-J3, hepatocyte growth factor, tumor necrosis factor-a, angiogenin, interleukin-8, and others (8, 15) . Work done by several laboratories over the last few years has elucidated the pivotal role of vascular endothelial growth factor (VEGF) in the regulation of normal and abnormal angiogenesis (5) . The recent finding that the loss of a single VEGF allele results in embryonic death is consistent with an irreplaceable role played by this factor in the development of the vascular system during embryogenesis (3, 4) . Recent evidence points to VEGF as a key mediator of neovascularization associated with tu-mors and proliferative retinopathies (5) . In situ hybridization studies demonstrated that the VEGF mRNA is markedly upregulated in the vast majority of human tumors that have been examined when compared with the surrounding tumor-free tissues (5) .
The availability of specific monoclonal antibodies capable of inhibiting VEGF-induced angiogenesis in vivo and in vitro made it possible to generate direct evidence for a role of VEGF in tumorigenesis. Several murine monoclonal antibodies were generated, using the 165amino acid isoform of recombinant humanized VEGF as an immunogen (13) . Among those, murine anti-VEGF monoclonal antibody A.4.6.1 (muMAb VEGF), which belongs to the IgG isotype, was found to consistently and potently neutralize the biologic activities of VEGF, including the endothelial cell mitogenic activity, the vascular permeability enhancing activity, and the angiogenic properties in the chick chorioallantoic membrane (13) . This antibody recognizes all isoforms of VEGE Although muMAB VEGF is a murine antibody, it is directed against human VEGE In I study (14) , muMAb VEGF was found to exert a potent inhibitory effect on the growth of 3 human tumor cell lines injected subcutaneously into nude mice: the SK-LMS-1 leiomyosarcoma, the G55 glioblastoma multiforme, and the A673 rhabdomyosarcoma. The growth inhibition ranged from 70% to >95%.
A maximal effect was observed at the dose of 5 mg/kg, administered intraperitoneally twice weekly (14) . These findings provided a direct demonstration that inhibition of the action of endogenous VEGF may result in suppression of tumor growth in vivo. The present study was conducted in tumor-bearing nude mice to evaluate the concentration-response relationship of muMAb VEGF for the purpose of estimating an efficacious plasma concentration of the recombinant humanized form (rhuMAb VEGF) in cancer patients. Additionally, the growth dynamics of the tumors were evaluated as a function of dose to explore whether a mechanismic interpretation of tumor growth inhibition by muMAb VEGF is possible. The A673 human rhabdomyosarcoma xenograft model was selected for this study because muMAb VEGF has demonstrated efficacy against this rapidly proliferating, highly vascularized, nonmetastatic human tumor (14) . METHODS Animals. One hundred eighty-eight female beige nude mice (16-24 g) were obtained from Life Sciences, Inc. (St. Petersburg, FL). Animals were maintained in microisolator cages within the barrier facility (22.8°C; 12-hr light/dark cycles) as per standard operating procedure for nude mice under a program accredited by the American Association for the Accreditation of Laboratory Animal Care. Food and water were available ad libitum. Forty animals were weighed individually at the start of the study to estimate average body weight. A673 (CRL 1598) human rhabdomyosarcoma cells (American Type Culture Collection) were injected subcutaneously (sc) in the dorsal area (2 X 106 cells/mouse in 0.2 ml) at the start of the study (day 1 ). Clinical signs were monitored daily throughout the study. At the end of the study, animals 10 for study of pharmacodynamics; 14 for study of pharmocokinetics.
were euthanatized with an overdose of pentobarbital administered intraperitoneally followed by exsanguination.
Test Materials. The animals were divided into 9 groups (Table I ). Group I (n = 10) received phosphatebuffered saline (PBS) as a control. Groups 2-8 (n = 24/ group) received muMAb VEGF A.4.6.1 (Genentech) at 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, and 5.0 mg/kg, respectively. Group 9 (n = 10) received anti-gpl20 isotype-matched control antibody (Genentech) at 5.0 mg/kg. Dosing began 24 hr after tumor implantation. Each animal received intraperitoneal (ip) injections of test material (0.1 ml) twice weekly (Tuesday and Friday) for a total of 8 doses (days 2, 5, 9, 12, 16, 19, 23, 26) . Animals were euthanatized before the completion of the study (a) if the tumors became necrotic, (b) if the tumors became excessively large and/or interferred with the animal's movement, or (c) if the animals were found moribund. For unscheduled euthanasia, the general protocol procedures were followed.
Pharmacodynamics. Ten mice/group were used to investigate the pharmacodynamics of muMAb VEGF Tumor dimensions (A, B, C), where A and B are the perpendicular diameters and C is height (in millimeters), were measured weekly (Tuesday). Tumor area (A X B) and volume (A X B X C) were computed. At time of euthanasia (day 30), EDTA plasma was collected for pharmacokinetics, and the tumor dimensions and tumor weight (in grams) were recorded.
Pharmacokinetics. Immediately prior to each dose, 2 mice/group (groups 2-8, n = 14 mice/group) were selected randomly, and EDTA plasma was collected for pharmacokinetics evaluation (trough concentrations). The animals were euthanatized, and the tumor dimensions and tumor weights were recorded. The last collection in these groups of animals occurred on day 26, with the final pharmacokinetic data, i.e., day 30 (week 4) supplied by the pharmacodynamic group animals.
Assay. Plasma concentrations of muMAb VEGF were measured by an enzyme-linked immunosorbent assay using recombinant human VEGF for coat and goat antimouse IgG F(ab' )~ HRP (Organon Teknaka Corp., Durham, NC) for detection. The lower limit of detection was 0.02 [Lg/ml, following a minimum 1:30 dilution in assay buffer.
PharmacokineticlPharmacodynamic Modeling. A single complementary exponential function was fitted to the muMAb VEGF plasma concentration versus time data
where C(t) is concentration, C~ is the asymptotic concen-tration, k is the elimination rate coefficient, and t is time.
The linearity of the system was examined by evaluating the relationship between the asymptotic concentration and dose.
Correlations between asymptotic concentrations and dose and between tumor weight, area, and volume were examined by fitting a power function to the data:
where y is the asymptotic concentration, tumor area, or tumor weight, x is dose, tumor volume, or tumor weight, a is the value of y at x = 1, and b determines the curvature of the function. When b = l, this function represents a proportionality relationship.
A hyperbolic function was fitted to the tumor response versus concentration/dose data at week 4 or at time of euthanasia:
where y(x) represents the tumor response (area, volume, or weight), x represents the measured or asymptotic muMAb VEGF plasma concentrations (or administered dose), ymax is the estimated maximal tumor size, Ymin is the estimated minimal tumor size (there is a minimum value because tumor growth was not completely suppressed), and K represents an estimated inhibition constant (equivalent to an IC,o or ID,,).
A sigmoidal growth (logistic) function was fitted to the tumor area versus time data:
where y(t) is tumor area, y-is the projected maximal tumor area at infinite time (i.e., t -~ (0), yo is the estimated starting tumor area at t = 0, and X is the growth rate coefficient. The maximal tumor area and the growth rate coefficient were evaluated as functions of dose to explore potential mechanismic explanations for the activity of muMAb VEGF in this tumor model.
The parameters of each function (i.e., C_, k, a, b, K, Ymax, Ymin' Yx, Yo, X) were estimated by a nonlinear leastsquares method using the Gauss-Newton-Marquardt-Levenberg procedure (17) , which includes estimates of the standard errors of the parameters. The search routine was implemented on a DELL 450 DE PC running HTBasic 386 for PC (TransEra, Provo, UT). Nominal sample collection times and dose concentrations were used in these analyses.
Estimation of Human Dosing Regimen. The concentration-response data in mice were used to estimate the plasma concentration of muMAb VEGF that is necessary for satisfactory tumor suppression ( Fig. 1 ). It was assumed that the same plasma concentration of rhuMAb VEGF in humans would be associated with clinical efficacy because the murine and human forms of the antibody have similar efficacy (IC51) in the adrenal cortex capillary endothelial cell bioassay and similar binding affinity (Kd) in the KDR-IgG competition binding assay. Human dosing regimens to achieve the target plasma concentrations were estimated by simulation, assuming that the pharmacokinetics of rhuMAb VEGF are similar to the pharmacokinetics of recombinant human anti- p 185HER2 monoclonal antibody (rhuMab HER2), a similar IgG, anticancer monoclonal antibody. The pharmacokinetics of muMAb VEGF in mice were compared with simulations based on the pharmacokinetics of muMAb 4D5 (the murine form of MAb HER2) in mice to determine if it is reasonable to assume that the 2 monoclonal antibodies would behave similarly in vivo. Although this mouse simulation model does not constitute proof that the humanized monoclonal antibodies will behave similarly in humans, it does provide a basis for the evaluation.
RESULTS AND DISCUSSION
The growth dynamics of the A673 human rhabdomyosarcoma in nude mice are displayed in Fig. 2 . Satisfactory tumor suppression (>65% tumor inhibition based on tumor area or >80% inhibition based on tumor volume) was achieved at doses of >50 ~,g/mouse. These results agree with earlier reports for this tumor model (14) . Furthermore, muMAb VEGF has shown in vivo inhibitory activity at doses of 50-100 pLg/mouse against different tumor cell lines, e.g., SK-LMS-1 leiomyosarcoma, G55 glioblastoma multiforme, LIM6 human colon carcinoma, and HM7 human colon carcinoma (14, 22) , suggesting that the results in the current study with A673 rhabdomyosarcoma are representative of the in vivo antitumor activity of this antibody.
There was a classic sigmoidal relationship between the mean tumor area per group and time after tumor implantation (Fig. 2) ; this sigmoidal character is indicative of limitations either within the cells or within their environ- ment, resulting in an inhibitory action on the cellular growth. Analysis of the relationships between the projected maximal tumor area (y-) or the growth rate coefficient (X) versus dose (Fig. 3 ) demonstrated that maximal tumor size declined as a function of dose (ID,o = 28 ~,gi mouse), whereas the growth rate coefficient was independent of dose (mean growth rate coefficient is 1.52/wk, which corresponds to a doubling time of 3.2 days). (The standard error [in percent] will appear in parentheses after each parameter estimate.) These results suggest that muMAb VEGF does not affect the doubling time; instead, the inhibitory action increases as a function of dose, resulting in the decline of the maximal tumor size (typically seen in dynamic cell cultures when they exhaust their nutrients). This result is consistent with the expected mechanism of action of MAb VEGF, which inhibits neovascularization in the growing tumor, thus depriving the cells of their nutrients.
The asymptotic concentration Cx of muMAb VEGF at each dose level was estimated by fitting a complementary exponential function (Eq. 1) to the muMAb VEGF plasma data (Table II) ). The upper panel shows the hyperbolic relationship between the projected maximal tumor area (yx) and dose, and the lower panel shows that the growth rate coefficient (X) is independent of dose. Parameter estimates for maximal tumor area: ymax = 809 mm2 (8%); Ymm = 0 mm2; ID50 = 28.0 jjbg (40%); mean value for growth rate coefficient (X) = 1.52/week (4%). collected just prior to each dose during the 4-wk study period; therefore, the asymptotic concentration represents a trough concentration. Because antibodies such as muMAb VEGF and anti-gpl20 are cleared slowly in mice, the fluctuations between peak and trough concentrations are minimal. The relationship between C_ and TABLE II.-The concentrations of muMAb VEGF and anti-gp 120 at each dose level. 11 Dose volume, 0.1 ml intraperitoneally twice a week. I The asymptotic concentration Cx of muMAb VEGF at each dose level was estimated by fitting a complementary exponential function (Eqn. 1 ) to the muMAb VEGF plasma concentration versus time data. The asymptotic concentration Cx of anti-gp120 was obtained by averaging the concentrations from plasma samples collected at time of sacrifice (there was not a pharmacokinetic subgroup for this treatment). The standard error estimate for the asymptotic concentration Cx appears in parentheses. I &dquo;Its&dquo; indicates lower than assay standard (0.02 f.lg/m1). dose is nonlinear (Fig. 4 ), which is not surprising. Nonlinear pharmacokinetics have been observed with monoclonal antibodies (19) , including rhuMAb HER2 (Genentech ; data on file). Figure 5 shows correlation plots between tumor weight, area, and volume for data collected at week 4. There is a proportionality relationship between tumor weight and volume. The tumor weight (in grams) is about a 0.5-multiple of the tumor volume (in cubic centimeters) (i.e., slope of ---0.5 g/cm3). This proportionality between tumor weight and volume means that these measures can be used interchangeably. The other 2 correlations were described by a power function (Eq. 2). The significance of the power (b) values (i.e., 0.631 for area-volume and 0.618 for area-weight) is that both are similar to the value 2/3, which corresponds to the theoretical value for the area/volume ratio. Also, these data suggest that either area (MM2) or volume (mm3) can be used to assess tumor growth dynamics.
Tumor weights at euthanasia for indiviual animals are displayed in Fig. 6 and demonstrate the biological variability that is customarily observed in studies of this nature. There is a hyperbolic relationship between the mean tumor weight at euthanasia and the dose of muMAb VEGF, and the corresponding ID,, has a value of about 8.6 pLg/mouse (48%). This IDso is not different from the ID5, for the mean tumor area-dose relationship (i.e., ID,, = 9.4 tJLg/mouse [72%]; data not shown). Figure 7 shows the semilogarithmic representation of the relationship between the individual tumor weight at euthanasia and the concentration of muMAb VEGF in plasma of the same animal. A hyperbolic function was fitted to these data to estimate an ICso of about 0.27 ~,g/ ml (58%). From visual inspection of these data, it is clear that concentrations > 10 pLg/ml are associated with maximal tumor suppression.
The relationship between the mean tumor area at week 4 and the estimated asymptotic concentration C, of muMAb VEGF for each dose is displayed in Fig. 8 . A hyperbolic function was fitted to these data to estimate an lC51 of about 2.1 jjLg/ml (83%). This IC,, is not different from the IC,, for the volume-concentration rela- There is a linear relationship between tumor weight and volume (y = ax). The other two correlations were described by a power function (i.e., y = axh). The values for the parameters (a, b) and the standard error estimates (shown in parentheses) are provided above each panel. tionship (i.e., lC51 = 1.9 [92%]; data not shown). Satisfactory tumor suppression in this nude mouse tumor model requires concentrations > 10 ~,g/ml and is assured at 30 pLg/ml (cf. the asymptotic concentration in the 50 pLg/mouse group; Table 2 ). The difference between the IC,o determined by the analysis of individual tumor areaconcentration relationships (Fig. 7 , IC,o = 0.27 )JLg/ml) and the lC5, determined from mean group data (Fig. 8 , IC,o = 2.1 )JLg/ml) demonstrates the effect of biologic and pharmacokinetic variability within groups (Fig. 6 and Table 2, respectively) on data analyses of this type. Careful monitoring of rhuMAb VEGF concentrations in clinical trials to assess kinetic/dynamic variability will establish if concentrations c 10 ~,g/ml are sufficient for efficacy. Estimation of Human Dosing Regimen. Pharmacoki-FIG. 6.-Tumor weight at euthanasia in individual animals, for all groups, displayed as a function of dose. s = the tumor weight in group I (PBS control), and c = the tumor weight in group 9 (anti-gp 120 control antibody). The insert shows the hyperbolic relationship between the mean tumor weight at euthanasia and the dose of muMAb VEGE Parameter estimates: y,,. = 8.07 g ( 11 %); ym,~ = 0 g; IDSO = 8.6 jig/ mouse (48%). For comparison, the same hyperbolic function has been superimposed on the semilogarithmic plot of the individual data (main plot).
netic data for muMAb VEGF were similar to the pharmacokinetics of muMAb 4D5 (the murine form of rhuMAb HER2) in nude mice (Fig. 9 ), thus fulfilling assumption 1 (Fig. 1) . A clinical dosing regimen for rhuMAb VEGF was designed assuming that (a) rhuMAb VEGF pharmacokinetics will resemble rhuMAb HER2 pharmacokinetics in humans (assumption 3 of muMAb VEGF and muMAb 4D5 in mice. The continuous line is a simulation based on historical muMAb 4D5 pharmacokinetics (Genentech ; data on file). The symbols are the actual plasma concentrations of muMAb VEGF in mice at that dose. The 2 antibodies have similar kinetics at a dose that provides satisfactory tumor suppression. Bottom: A dosing regimen of rhuMAb VEGF in humans was designed to achieve plasma concentrations comparable to the efficacious concentrations in the preclinical studies. The simulated dosing regimen (based on historical rhuMAb HER2 pharmacokinetics) represents a 4 mg/kg iv bolus dose to start, followed by a 2 mg/kg iv bolus dose weekly. trough plasma concentrations should be approximately 10-30 ~,glml (assumption 2). From this assumption-rich analysis, a 4 mg/kg rhuMAb VEGF intravenous (iv) bolus loading dose followed by 2 mg/kg iv weekly is expected to maintain the plasma concentrations in the appropriate efficacious range (Fig. 9 ). Actual dosing regimens for rhuMAb VEGF can be adjusted in phase II, as necessary, when the human pharmacokinetic data become available. Uncertainties as to the degree of pharmacokinetic/dynamic variability that will be observed in the clinical setting and the fact that the tumors (or metastases) in patients might be well established (unlike the situation in mice in which treatment begins 24 hr after implantation) make 30 ~,g/ml a reasonable but unproven target plasma concentration for rhuMAb VEGE Careful monitoring of rhuMAb VEGF concentrations in patients will establish if concentrations < )JLg/ml are sufficient for efficacy.
CONCLUDING REMARKS
This study shows one approach that can be used to estimate a human dosing regimen from preclinical pharmacokinetic/pharmacodynamic data. It is advantageous to predict the human dosing regimen early in drug development (i.e., prior to Investigational New Drug [IND] application) for several reasons: (a) to establish the human dose in relation to preclinical efficacy models, (b) to evaluate that dose (and multiples of that dose) in the IND safety studies, and (c) to estimate the 'cost of goods' in relation to other available therapies (if the cost is deemed exorbitant, then a more potent, higher affinity molecule or a molecule with a lower clearance that can be administered less frequently may be a better candidate for development).
The results of this study suggest that rhuMAb VEGF plasma concentrations > 10-30 ~,g/ml will be required for clinical efficacy. During the preclinical development of rhuMAb HER2, we showed that muMAb 4D5 (the murine form of rhuMAb HER2) was efficacious in nude mouse tumor models at concentrations > 10 ~,g/ml, and similar concentrations of rhuMAb HER2 have been associated with efficacy in breast cancer clinical trials (1), confirming the usefulness of these preclinical models.
Less frequent dosing schedules (such as every 2 wk or once/month instead of weekly) would be easier to manage in the clinic, although this would require higher doses and would produce larger swings between the peak and trough rhuMAb VEGF plasma concentrations. The impact of this type of plasma concentration profile on efficacy (or safety) is not known. The potential for kinetic/ dynamic interferences in patients, such as with circulating VEGF or other substances in the plasma or tissues (especially tumor tissues) that can bind or otherwise inactivate rhuMAb VEGF or change the clearance and distribution characteristics, although remote, cannot be overlooked and could have a substantial impact on these human dosing projections.
